1998
Cytokine secretion of myelin basic protein reactive T cells in patients with multiple sclerosis
Windhagen A, Anderson DE, Carrizosa A, Balashov K, Weiner HL, Hafler DA. Cytokine secretion of myelin basic protein reactive T cells in patients with multiple sclerosis. Journal Of Neuroimmunology 1998, 91: 1-9. PMID: 9846813, DOI: 10.1016/s0165-5728(98)00086-1.Peer-Reviewed Original ResearchConceptsMBP-reactive T cellsReactive T cellsChronic progressive multiple sclerosisProgressive multiple sclerosisMultiple sclerosisT cellsCytokine secretionMyelin basic proteinT cell linesNormal controlsMyelin basic protein-reactive T cellsAntigen-specific cytokine secretionMyelin-reactive T cellsNormal individualsShort-term T cell linesAutoreactive T cell linesCP MS patientsIL-12/IL-4/MBP-reactive cellsTh2-type phenotypeRR-MS patientsTh2 cytokine secretionAutoreactive T cellsMore IFN-gamma
1995
Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis.
Balashov KE, Khoury SJ, Hafler DA, Weiner HL. Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis. Journal Of Clinical Investigation 1995, 95: 2711-2719. PMID: 7769110, PMCID: PMC295954, DOI: 10.1172/jci117973.Peer-Reviewed Original ResearchConceptsAutologous mixed lymphocyte reactionProgressive multiple sclerosisChronic progressive multiple sclerosisInduction of CD8Tact cellsMultiple sclerosisT cellsHuman CD8Suppressive propertiesAutologous T cellsRelapsing-remitting MST cell responsesHuman autoimmune diseasesMixed lymphocyte reactionGM-CSF antibodySuppressive CD8Autologous antigenLymphocyte reactionAutoimmune diseasesBeta antibodyGamma antibodyCD8Proliferative responseSpecific cytokinesNormal controls
1991
Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis
Hafler D, Orav J, Gertz R, Stazzone L, Weiner H. Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis. Journal Of Neuroimmunology 1991, 32: 149-158. PMID: 1672870, DOI: 10.1016/0165-5728(91)90007-t.Peer-Reviewed Original ResearchConceptsT cell populationsDisability Status ScaleMixed lymphocyte reactionSpontaneous proliferationT cellsImmune measuresACTH infusionImmune functionChronic progressive multiple sclerosisProgressive multiple sclerosis patientsCD4/CD8 ratioCell populationsAllogeneic mixed lymphocyte reactionFunctional immune measuresPeripheral blood CD4Progressive multiple sclerosisPositive clinical responsePositive T cellsMultiple sclerosis patientsFunctional immune assaysLevels of proliferationBlood CD4CD8 ratioClinical improvementClinical responseInterleukin-1 corrects the defective autologous mixed lymphocyte response in multiple sclerosis
Hafler D, Chofflon M, Kurt-Jones E, Weiner H. Interleukin-1 corrects the defective autologous mixed lymphocyte response in multiple sclerosis. Clinical Immunology 1991, 58: 115-125. PMID: 1670583, DOI: 10.1016/0090-1229(91)90153-2.Peer-Reviewed Original ResearchConceptsAutologous mixed lymphocyte reactionMultiple sclerosisWhole T cellsMS patientsT cellsImmune defectsChronic progressive multiple sclerosisNon-T cell populationsAutologous mixed lymphocyte responseProgressive multiple sclerosisMixed lymphocyte responseMixed lymphocyte reactionResponse of CD4T cell populationsSex-matched controlsT cell regulationIL-1 secretionCell populationsLymphokine IFN-gammaImmunoregulatory defectsLymphocyte responsesRIL-2Lymphocyte reactionMS subjectsAutoimmune diseases
1988
Cumulative Experience with High‐Dose Intravenous Cyclophosphamide and ACTH Therapy in Chronic Progressive Multiple Sclerosis
CARTER J, DAWSON D, HAFLER D, FALLIS R, STAZZONE L, ORAV J, WEINER H. Cumulative Experience with High‐Dose Intravenous Cyclophosphamide and ACTH Therapy in Chronic Progressive Multiple Sclerosis. Annals Of The New York Academy Of Sciences 1988, 540: 535-536. PMID: 2849902, DOI: 10.1111/j.1749-6632.1988.tb27163.x.Peer-Reviewed Original ResearchConceptsChronic progressive multiple sclerosisHigh-dose intravenous cyclophosphamideProgressive multiple sclerosisACTH therapyIntravenous cyclophosphamideMultiple sclerosisCumulative experienceCyclophosphamideSclerosisTherapyAnti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses.
Hafler DA, Ritz J, Schlossman SF, Weiner HL. Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses. The Journal Of Immunology 1988, 141: 131-8. PMID: 2454256, DOI: 10.4049/jimmunol.141.1.131.Peer-Reviewed Original ResearchConceptsHuman anti-mouse antibodiesAnti-mouse responseAnti-mouse antibodiesHuman anti-mouse responseMultiple sclerosisChronic progressive multiple sclerosisPhase I clinical studyAnti-CD2 monoclonal antibodiesProgressive multiple sclerosisMore chronic diseasesT cell subpopulationsHuman immune responseT cell activationAcute immunosuppressionMAb infusionsT cell surfaceAnti-CD4Daily infusionsImmunologic responseImmunosuppressive effectsChronic diseasesIgG isotypeClinical studiesImmune responseLike antibodiesImmunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
Carter JL, Hafler DA, Dawson DM, Orav J, Weiner HL. Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology 1988, 38: 9-14. PMID: 2838768.Peer-Reviewed Original ResearchConceptsProgressive multiple sclerosisChronic progressive multiple sclerosisMultiple sclerosisShorter disease durationMajority of patientsDosage of medicationCurrent treatment programsInduction regimenComplication rateDisease durationFrequent complicationLate complicationsYounger patientsPermanent remissionTreatment regimenInitial treatmentBooster injectionMaintenance treatmentMinor infectionsPatientsRemissionTreatment programRegimenComplicationsSingle treatmentImmunosuppression with monoclonal antibodies in multiple sclerosis.
Hafler DA, Weiner HL. Immunosuppression with monoclonal antibodies in multiple sclerosis. Neurology 1988, 38: 42-7. PMID: 3260356.Peer-Reviewed Original ResearchConceptsHuman anti-mouse antibodiesChronic progressive multiple sclerosisAnti-T cell mAbsAnti-mouse antibodiesProgressive multiple sclerosisMAb infusionsMultiple sclerosisChronic diseasesT11 mAbPhase I clinical studyAnti-idiotypic activityMonoclonal antibody infusionMore chronic diseasesT cell subpopulationsAnti-mouse responseHuman immune responseAnti-idiotypic antibodiesHuman anti-mouse responseT cell activationAcute immunosuppressionT cell surfaceAntibody infusionImmunologic responseRepeated administrationIgG isotype
1987
Oligocllonal T lymphocytes in the cerebrospinal fluid (CSF) of patients with chronic progressive multiple sclerosis
Hafler D, Duby A, Lee S, Seidman D, Weiner H. Oligocllonal T lymphocytes in the cerebrospinal fluid (CSF) of patients with chronic progressive multiple sclerosis. Journal Of Neuroimmunology 1987, 16: 69. DOI: 10.1016/0165-5728(87)90234-7.Peer-Reviewed Original ResearchCerebrospinal fluidChronic progressive multiple sclerosisProgressive multiple sclerosisMultiple sclerosisT lymphocytesSclerosisPatientsLymphocytesImmunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies.
Dawson DM, Carter JL, Hafler DA, Weiner HL. Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies. Nuova Rivista Di Neurologia 1987, 57: 88-91. PMID: 3039645.Peer-Reviewed Original ResearchConceptsProgressive multiple sclerosisMonoclonal antibody therapyMultiple sclerosisAntibody therapyChronic progressive multiple sclerosisHigh-dose intravenous cyclophosphamideMultiple sclerosis patientsForm of treatmentLong-term controlIntravenous cyclophosphamideSclerosis patientsClinical resultsSerious toxicityImmune parametersPilot trialCyclophosphamideNervous systemSclerosisTerm controlsPatientsMonoclonal antibodiesACTHOnly small numbersTherapyAdverse effects